275 related articles for article (PubMed ID: 35899413)
1. Bringing pharmacomicrobiomics to the clinic through well-designed studies.
Steiner HE; Patterson HK; Giles JB; Karnes JH
Clin Transl Sci; 2022 Oct; 15(10):2303-2315. PubMed ID: 35899413
[TBL] [Abstract][Full Text] [Related]
2. Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions.
Aziz RK; Hegazy SM; Yasser R; Rizkallah MR; ElRakaiby MT
Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1043-1055. PubMed ID: 30269615
[TBL] [Abstract][Full Text] [Related]
3. Targeting the gut microbiome to control drug pharmacomicrobiomics: the next frontier in oral drug delivery.
Kamath S; Stringer AM; Prestidge CA; Joyce P
Expert Opin Drug Deliv; 2023; 20(10):1315-1331. PubMed ID: 37405390
[TBL] [Abstract][Full Text] [Related]
4. Pharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment.
Jia L; Huang S; Sun B; Shang Y; Zhu C
Front Endocrinol (Lausanne); 2023; 14():1149256. PubMed ID: 37033254
[TBL] [Abstract][Full Text] [Related]
5. The impact of common pharmaceutical excipients on the gut microbiota.
Subramaniam S; Kamath S; Ariaee A; Prestidge C; Joyce P
Expert Opin Drug Deliv; 2023; 20(10):1297-1314. PubMed ID: 37307224
[TBL] [Abstract][Full Text] [Related]
6. Interaction between drugs and the gut microbiome.
Weersma RK; Zhernakova A; Fu J
Gut; 2020 Aug; 69(8):1510-1519. PubMed ID: 32409589
[TBL] [Abstract][Full Text] [Related]
7. Role of the gut microbiome in cardiovascular drug response: The potential for clinical application.
Steiner HE; Gee K; Giles J; Knight H; Hurwitz BL; Karnes JH
Pharmacotherapy; 2022 Feb; 42(2):165-176. PubMed ID: 34820870
[TBL] [Abstract][Full Text] [Related]
8. Gut Reactions: Breaking Down Xenobiotic-Microbiome Interactions.
Clarke G; Sandhu KV; Griffin BT; Dinan TG; Cryan JF; Hyland NP
Pharmacol Rev; 2019 Apr; 71(2):198-224. PubMed ID: 30890566
[TBL] [Abstract][Full Text] [Related]
9. Connecting the dots: Targeting the microbiome in drug toxicity.
Luo Y; Zhou T
Med Res Rev; 2022 Jan; 42(1):83-111. PubMed ID: 33856076
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects.
Leigh SJ; Lynch CMK; Bird BRH; Griffin BT; Cryan JF; Clarke G
Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):5-26. PubMed ID: 35176217
[TBL] [Abstract][Full Text] [Related]
11. Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism.
Dikeocha IJ; Al-Kabsi AM; Miftahussurur M; Alshawsh MA
FASEB J; 2022 Jun; 36(6):e22350. PubMed ID: 35579628
[TBL] [Abstract][Full Text] [Related]
12. Drug-microbiota interactions: an emerging priority for precision medicine.
Zhao Q; Chen Y; Huang W; Zhou H; Zhang W
Signal Transduct Target Ther; 2023 Oct; 8(1):386. PubMed ID: 37806986
[TBL] [Abstract][Full Text] [Related]
13. Methodological challenges in neonatal microbiome research.
Chapman JA; Stewart CJ
Gut Microbes; 2023; 15(1):2183687. PubMed ID: 36843005
[TBL] [Abstract][Full Text] [Related]
14. Conducting research on diet-microbiome interactions: A review of current challenges, essential methodological principles, and recommendations for best practice in study design.
Shanahan ER; McMaster JJ; Staudacher HM
J Hum Nutr Diet; 2021 Aug; 34(4):631-644. PubMed ID: 33639033
[TBL] [Abstract][Full Text] [Related]
15. Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine.
Hassan R; Allali I; Agamah FE; Elsheikh SSM; Thomford NE; Dandara C; Chimusa ER
Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33253350
[TBL] [Abstract][Full Text] [Related]
16. Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?
Sharma A; Buschmann MM; Gilbert JA
Clin Pharmacol Ther; 2019 Aug; 106(2):317-328. PubMed ID: 30937887
[TBL] [Abstract][Full Text] [Related]
17. Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment.
Rana D; Salave S; Perla A; Nadkarni A; Kolhe S; Jindal AB; Mandoli A; Dwivedi P; Benival D
Curr Drug Targets; 2022; 23(9):869-888. PubMed ID: 35264088
[TBL] [Abstract][Full Text] [Related]
18. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
19. A data-driven approach for predicting the impact of drugs on the human microbiome.
Algavi YM; Borenstein E
Nat Commun; 2023 Jun; 14(1):3614. PubMed ID: 37330560
[TBL] [Abstract][Full Text] [Related]
20. Early-Life Nutrition and Microbiome Development.
Isolauri E; Rautava S; Salminen S; Collado MC
Nestle Nutr Inst Workshop Ser; 2019; 90():151-162. PubMed ID: 30865983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
